Abstract:
The present invention relates to the use of a composition including of at least a mutated antithrombin
       having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or   having no anticoagulant activity,
 
for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury.

Description:
FIELD OF THE INVENTION 
     The present invention relates to mutated antithrombins and their use as drugs. The present invention also discloses a process for preparing mutated antithrombins. 
     BACKGROUND OF THE INVENTION 
     Physiology 
     Systemic activation of the coagulation system is frequently observed in patients with severe sepsis and/or septic shock. Severe sepsis, as a complication of infection, is characterized by systemic inflammation, activation of proteolytic cascades, coagulation abnormalities (DIC), and various organ dysfunctions. Its more severe form, septic shock, associates in addition altered hemodynamic and impaired organ perfusion, aggravating further organ failure and frequently leading to death in multiorgan failure. Mortality in septic shock is high (40% to 50%), and rises tremendously with the number of failing organs, i.e. patients requiring renal replacement therapy for acute renal failure may have mortality rate above 80%. The initiating event for the development of severe sepsis is the activation of monocytes/macrophages by microbial antigens (i.e. lipopolysaccharide (LPS) liberated from Gram-negative bacteria, lipoteichoic acid from Gram-positive bacteria, fungal antigen) via binding to surface Toll-like receptors (Cohen J.  The immunopathogenesis of sepsis. Nature.  2002; 420:885-91). 
     Mechanistic 
     Monocyte/macrophages activation, potentially followed by endothelial cells activation, results in secretion of cytokine mediators (such as interleukin 6 (IL-6), tumor necrosis factor (TNFα) and chemokines, lipid mediators, adhesion molecules and tissue factor expression at the cell membrane, nitric oxyde and oxygen reactive species formation). This step is followed by the activation of biological cascades including the coagulation and the complement, which contribute to the maintenance of the inflammatory reaction and coagulation activation. These events are fully adapted to eradicate microbial agents at the site of infection, but results in deleterious consequences, i.e. various organ failures, if they become widespread, unregulated and sustained. (Aird W.  The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood.  2003; 101:3765-77). 
     Tissue factor expression leads to uncontrolled generation of thrombin from its precursor molecule prothrombin. Endogenous anticoagulants, namely antithrombin (AT), protein C pathway and Tissue Factor Pathway Inhibitor, as well as the fibrinolytic system are activated and function to regulate thrombin generation and its consequences. However, blood levels of endogenous inhibitor are diminished due to their consumption onto their substrate, inhibited synthesis and cleavage by several proteases. Indeed, AT levels decrease precipitously in the early phases of severe sepsis. Fibrinolysis is rapidly inhibited by the production of plasminogen activator inhibitor-1. Thus, a procoagulant state develops in patients with sepsis potentially leading to overt disseminated intravascular coagulation (DIC), which has deleterious effects. Diffuse thrombus formation throughout microcirculation can compromise tissue perfusion to critical organs, and cellular effects of various coagulation proteins participate in the general inflammatory syndrome (Aird W.  The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood.  2003; 101:3765-77). It is demonstrated that coagulation abnormalities in severe sepsis is associated with poor outcome. Notably, depletion of AT in septic shock portends a poor prognosis (Fourrier F.  Septic shock, multiple organ failure, and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest.  1992; 101:816-823). 
     Antithrombin 
     Antithrombin plays an essential role in maintaining the fluidity of blood. Blood coagulation is mediated by a series of serine proteases. Antithrombin is a potent inhibitor of coagulation serine proteases, in particular, Factors IIa (thrombin), Xa, IXa and XIa. Interaction of AT with heparin-like glycosaminoglycans (HGAGs) on endothelial cells is important for the acceleration of thrombin inhibition by AT (Rosenberg R D.  Biochemistry of heparin antithrombin interactions, and the physiologic role of this natural anticoagulant mechanism. Am J Med.  1989; 87:2S-9S). Indeed, thrombotic episodes have been observed in patients with congenital AT deficiency and in those with variant AT that lacks affinity for heparin suggesting that the interaction of AT with the endothelial cell surface heparin-like GAGs is important for regulation of the coagulation cascade by AT (Kuhle S, Lane D A, Jochmanns K, Male C, Quehenberger P, Lechner K, Pabinger I.  Homozygous antithrombin deficiency type II  (99  Leu to Phe mutation )  and childhood thromboembolism. Thromb Haemost.  2001; 86:1007-11). The physiological importance of antithrombin in preventing excessive coagulation is revealed by studies of individuals whose antithrombin levels are decreased due to heredity or acquired deficiency. Such persons are prone spontaneous thrombosis and the associated risks of disseminated intravascular coagulation, cardiac infarction, cerebrovascular accident and pulmonary embolism. 
     In addition, AT has been shown to exert cytoprotective properties, through its binding to the glycosaminoglycans present on endothelial cells surface Indeed, AT inhibits NFkB activation endothelial cells and monocytes, resulting in an increase in prostacyclin synthesis, a decrease in pro-inflammatory cytokines production (IL6 and TNFα), a reduction in tissue factor exposure on endothelial cells or monocytes, a reduction in platelet aggregation and in endothelial cells/neutrophil interactions. This effect is abolished by heparin, through a competition process. These cytoprotective effects were observed for AT concentrations ranging from 2.5 to 40 UI/ml (corresponding to 2.5 to 40 fold normal circulating AT levels). 
     Models of Sepsis 
     AT has been shown to be efficacious in several experimental models of sepsis and septic shock, regardless of the species investigated, as shown in baboons, dogs, sheep, rabbits, rats, and chicken embryos. AT in these models proved to be effective after inducing a sepsis or septic shock with different agents including live bacteria ( Escherichia coli, Klebsiella pneumoniae ) and bacterial lipopolysaccharide (LPS). 
     In a guinea pig model, it has been demonstrated that AT could prevent DIC and organ hemorrhage and improve mortality after infection with the Gram-positive bacterium  Staphylococcus aureus.    
     Due to the missregulation of coagulation process during sepsis, some anticoagulants have been assayed in human, such as heparin or antithrombin. 
     Therapeutic doses of heparin (Corrigan J J.  Heparin therapy in bacterial septicemia. J Pediatr.  1977; 91:695-700) or antithrombin (Schipper H G, Jenkins C S P, Kahl L H, ten Cate J W.  Antithrombin III transfusion in disseminated intravascular coagulation. Lancet.  1978; 1:854-856) have been used clinically for more than 20 years for the prevention and treatment of disseminated intravascular coagulation and sepsis, without any clear evidence of efficacy. 
     In order to treat activation of coagulation system and depletion of anticoagulant during severe sepsis, some studies have been made in patients by using high doses of antithrombin. 
     Warren et al. ( High dose Antithrombin III in severe sepsis,  2008,  JAMA,  286(15), 1869-1878) have tested the effect of administration of 30,000 IU (cumulative dose for a 4-day treatment) AT in patients in a randomized controlled trial study. Patients receiving AT treatment had plasma AT levels around 180% of normal circulating blood levels, these levels being lower than doses required to achieve a cytoprotective effect. This study could not demonstrate the efficiency of AT administration on patient survival. Moreover, the authors have demonstrated that the administration of AT, at this dosage, enhances the hemorrhagic risk in patients, said risk being increased when patient has received a concomitant administration of heparin. 
     A post-hoc analysis of this study focusing on DIC related to severe sepsis reported that this dosage of AT (30,000 IU over 4 days) increases the hemorrhagic risk in patients without heparinic treatment, compared to control treated with a placebo ( Treatment effects of high - dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation,  2006,  J. of Thrombosis and Haemostasis,  4: 90-97), 
     Another study (Eisele at al.  Antithrombin III in patients with severe sepsis, intensive care Med.,  1998, 24:663-672) has demonstrated that 18,000 UI (cumulative dose for a 5-day treatment) of AT have some benefits in patient survival, without bleeding problems. However, the panel of patients used in this study is too small to be sure that this dosage of AT has no effect on bleeding, and the dosage of AT remains under the identified efficient dosage of antithrombin necessary to provide a good cytoprotective effect: indeed, in this study, patients receiving AT treatment had AT levels ranging from 70 to 130% of normal circulating AT levels. 
     So there is a need to provide new medicines for treating severe sepsis, which enhances the anticoagulation system in the patient, but without causing hemorrhagic accidents. 
     Other anticoagulant has been tested in the treatment of severe sepsis. 
     Activated protein C (drotrecogin α) has been shown to reduce severe sepsis mortality in patients with the highest severity scores [Bernard G R, Vincent J L, Laterre P F, LaRosa S P, Dhainaut J F, Lopez-Rodriguez A, Steingrub J S, Garber G E, Helterbrand J D, Ely E W, Fisher C J Jr;  Recombinant human protein C Worldwide Evaluation in Severe Sepsis  ( PROWESS )  study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med  2001; 344:699-709]. In spite of the results of this study, the use of activated protein C remains controversial, as controversy regarding the efficacy/safety profile of this drug notably regarding bleeding. WO2005/007820 discloses the use of a mutated activated protein C variants, with reduced anticoagulant activity, for the treatment of pathologies requiring a cellular cytoprotection, but these variants have not been tested in clinical practice [Kerschen E J, Fernandez J A, Cooley B C, Yang X V, Sood R, Mosnier L O, Castellino F J, Mackman N, Griffin J H, Weiler H.  Endotoxemia and sepsis mortality reduction by non - anticoagulant activated protein C. J Exp Med.  2007 Oct. 1; 204(10):2439-48.]. 
     Thus, it is important to provide a new medicine that can cure all the forms of severe sepsis, without causing any, or reduced only, hemorrhagic manifestation in patients. 
     SUMMARY OF THE INVENTION 
     So, one aim of the invention is to provide a new drug. 
     Also, another aim of the invention is to provide a new pharmaceutical composition comprising modified antithrombin as an active substance. 
     The invention relates to the use of a composition comprising of at least a mutated antithrombin:
         having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or   having substantially no anticoagulant activity,       

     for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury. 
     The term &lt;&lt;mutated antithrombin&gt;&gt; designates an antithrombin, preferably a human antithrombin, comprising at least a substitution, insertion and/or deletion of one or more amino acids within its amino acid sequence. 
     The said mutated antithrombins can be prepared according to the method described in the experimental part I/. 
     The human antithrombin sequence is described in Olds R. J., Lane D. A., Chowdhury V., De Stefano V., Leone G. and Thein S. L. “Complete nucleotide sequence of the antithrombin gene: evidence for homologous recombination causing thrombophilia”  Biochemistry.  32 (16), 4216-4224 (1993). 
     The human antithrombin sequence of the invention is a  Homo sapiens  serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINC1), mRNA. Accession NM 000488, Version NM 000488.2, GI:50541941. 
     There are many references which describe said DNA sequence (with signal peptide) but they are not absolutely identical because of the many natural polymorphisms of antithrombin which generally do not change the properties, i.e. the anticoagulant properties, of the antithrombin. 
     The human aminosequence of antithrombin presents two forms: a “short form” (SEQ ID NO: 2) which does not comprise a signal peptide and a “long form” (SEQ ID NO: 26) which includes a signal peptide. 
     The signal peptide comprises 32 amino acids and is necessary for antithrombin secretion. It is removed during antithrombin processing and the plasma antithrombin circulates as the &lt;&lt;short form&gt;&gt;. 
     Accordingly, in the present invention, the mutated antithrombin amino acid sequences, represented by SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 62, 64, 66, 68 and 78 do not comprise the signal peptide and the mutated antithrombin amino acid sequences, represented, by SEQ ID NO: 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 70, 72, 74, 76 and 80 include the signal peptide. 
     The term &lt;&lt;mutated antithrombin&gt;&gt; as used herein, designates mutated antithrombins which are different from the naturally found mutated antithrombin (also called mutants of antithrombin) known in the art in that said mutated antithrombins of the invention have a reduced or no anticoagulant activity, and are able to compete in vivo with plasma antithrombin for glycosaminoglycan binding. 
     It has unexpectedly been found that the said mutated antithrombins according to the invention are able to prevent the undesired complications of anticoagulation, in particular hemorrhages, resulting from side effects of said anticoagulant activity of antithrombin. 
     The expression &lt;&lt;mutated antithrombin having substantially no activity&gt;&gt; designates a mutated antithrombin which has lost its capacity to inhibit coagulation. 
     The expression &lt;&lt;mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non-mutated antithrombin&gt;&gt; designates a mutated antithrombin which has a reduced (2 to 20 fold reduced) capacity to inhibit coagulation compared to the wild type antithrombin. 
     The anticoagulant activity of mutated antithrombin will be evaluated in a purified system: mutated antithrombin anti-Xa and anti-IIa inhibitory activities will be measured as described in Material and methods section. 
     The mutated antithrombin according to the invention has a cytoprotective activity. This “cytoprotective activity” confers to mutated antithrombin properties to protect cells against damage or cellular injuries, such as damage caused by inflammation, infection or ischemia/hypoxia. 
     The cytoprotective activity of mutated antithrombin are evaluated as described in Material and methods section: briefly, the pro-inflammatory cytokines levels are compaired (IL6 and TNFα) in whole blood exposed to LPS, in the presence or in the absence of mutated antithrombin. 
     The expression “cellular injury” refers to a damage caused to the structure or function of the cell caused by an agent which may be physical or chemical. Cellular injury occurs when limits of adaptive response to a stimulus are exceeded. 
     Cellular injury can be caused by, but not limited to, inflammation, infection, hypoxia and ischemia/reperfusion. 
     Ischemia occurs when arterial flow is impeded by arteriosclerosis or by thrombi and is the most common cause of hypoxia, occurs during an inadequate oxygenation of the blood due to cardiorespiratory failure, or during a loss of oxygen-carrying capacity of the blood as in anemia or carbon monoxide poisoning. 
     Cellular injury can be reversible or irreversible. In the case of an irreversible injury, many cells will undergo apoptosis or necrosis. Necrosis, which is the more common type of cell death, is manifested by severe cell swelling or cell rupture, coagulation of cytoplasmic proteins, breakdown of cell organelles such as lysosomes, etc. . . . 
     Since heparin may compete with the interaction between mutated antithrombin and cellular heparin-like glycosaminoglycans, the mutated antithrombin according to the invention is preferably not administered in patients that have received heparin treatment. Other anticoagulants can be used in association with the mutated antithrombin of the invention, provided that said association does not impair the cytoprotective activity of mutated antithrombin. 
     More preferably, the present invention relates to the use of a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having substantially no anticoagulant activity, for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury, said mutated antithrombin being administered in a patient in a need thereof at a concentration from about 0.5 to about 15 UI/ml, particularly from about 1 to about 7.5 UI/ml to reach about 100% to 750% of AT in plasma (cytoprotective effects were observed for AT concentrations more than to 250%, with plasmatic AT).1 IU of antithrombin is defined as the amount of antithrombin contained in 1 mL of plasma, corresponding to a range from about 0.15 g/L to about 0.3 g/L of plasma. 
     According to the invention, mutated AT is thus preferably administered with a loading dose from about 3000 to about 22500 IU (40 à 300 IU/kg) followed by a continuous intravenous infusion from about 3000 to about 22500 IU (40 à 300 IU/kg) for a period of time from 2 to 7 days, preferably 4 days. 
     The invention relates to a method for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation hypoxia or ischemia/reperfusion injury, comprising the administering in a patient in a need thereof of a composition comprising at least one mutated antithrombin:
         having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or   having substantially no anticoagulant activity,       

     said composition being administered at a dosage from about 20 UI/kg/day to about 600 UI/kg/day, preferably from about 40 UI/kg/day to about 300 UI/kg/day. 
     In a preferred embodiment, the invention relates to the use of a composition comprising at least a mutated antithrombin defined above, for the preparation of a drug intended for the treatment or prevention of pathologies related to cellular ischemia/reperfusion injury, in particular selected from the group comprising: Inflammatory syndromes, cardiovascular diseases, neural or brain diseases, ischemia/reperfusion injury related to surgery, organ transplantation and ischemia/reperfusion injury related to stroke, or for the treatment or prevention of pathologies related to infections, in particular selected from the group comprising infectious diseases, and inflammation associated diseases. 
     An advantageous embodiment of the invention relates to the use of a composition comprising at least a mutated antithrombin above-defined, wherein said pathologies are selected from the group comprising: sepsis, severe sepsis or septic shock ischemic stroke, heat stroke, acute myocardial infarction, extremity ischemia, acute neurodegenerative disease, chronic neurodegenerative disease, such as Alzheimer&#39;s disease, Down syndrome, Huntington&#39;s disease, and Parkinson&#39;s disease, organ transplantation, chemotherapy, and radiation injury, such as brain radiation injury. 
     According to the invention, “hypoxic injury” means hypoxia or ischemia/reperfusion. Definition and classification of severe sepsis is known in the art, and for instance is disclosed in Levy, M. M., et al., (Levy, M. M., et al. Intensive Care Med, 2003. 29(4): p. 530-8. 
     A stroke (acute cerebrovascular attack) occurs when the blood flow to the brain is decreased or stopped. 
     In one preferred embodiment, the present invention relates to the use of mutated antithrombin as defined above for the preparation of a drug/medicine intended for the prevention or the treatment of sepsis; i.e. systemic inflammatory response syndrome (SIRS) accompanying an infective disease. Examples of syndromes caused by the aggravation of sepsis include severe sepsis, septic shock, and multiple organ dysfunction syndrome. 
     In one particular embodiment, the invention relates to the above-mentioned use, wherein said mutated antithrombin has:
         a thrombin inhibitory activity substantially reduced, or substantially lost, or   a factor Xa inhibitory activity reduced, or substantially lost, or   a thrombin inhibitory activity and a factor Xa inhibitory activity substantially reduced, or substantially lost.       

     The complete anticoagulant activity of antithrombin is achieved by the inhibition of the pro-coagulating activity of thrombin and factor Xa. Therefore, in order to reduce the anticoagulant activity of antithrombin it is possible to reduce, by mutation, its ability to inhibit thrombin, and/or factor Xa. Preferably, in order to completely reduce the anticoagulant activity of antithrombin, both of the thrombin and factor X inhibitory activity of antithrombin should be inactivated. 
     The thrombin inhibitory or factor Xa activity is “substantially reduced” means that the activity of antithrombin to inhibit thrombin or factor Xa is reduced compared to said activity in wild type antithrombin. Preferably, according to the invention, the thrombin inhibitory or factor Xa activity is considered as reduced when said activity represents from about 50% to about 5% of the thrombin inhibitory or factor Xa activity of the wild type antithrombin. 
     Anti-Xa and anti-IIa inhibitory activities will be measured in a purified system as described in Material and methods section. 
     The thrombin inhibitory or factor Xa activity is “substantially lost” means that the activity of antithrombin to inhibit thrombin or factor Xa is absent compared to said activity in wild type antithrombin. 
     Anti-Xa and anti-IIa inhibitory activities are measured in a purified system as described in “Material and methods” section. 
     In one other preferred embodiment, the invention relates to the above-mentioned use, wherein said mutated antithrombin comprises at least one mutation within the region from the amino acid at position 380 to the amino acid at position 400, particularly within the region from the amino acid at position 390 to the amino acid at position 397, particularly within the region from the amino acid at position 390 to the amino acid at position 394, in particular at positions 393 or 394, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2, said mutation being a substitution, insertion or deletion. 
     The region from the amino acid at position 380 to the amino acid at position 400 is generally named “reactive center loop” (RCL). The residues in the RCL are numbered according to their positions relative to the scissile P1-P1′ bond (non-primed numbers towards the N-terminus and primed numbers towards the C-terminus of the serpin). In particular, the region stretching from P14 to P4′ (residues from 380 to 397) is complementary to the active site of its target protease. In particular, residues from P4 to P1′ (residues from 390 to 394) directly interact within protease catalytic groove. In particular, residue P1 (393) is crucial for protease inhibition. 
     The mutated antithrombins of the invention can comprise others mutations, outside of the region from the amino acid at position 380 to the amino acid at position 400, provided there is no change in the above-mentioned properties of the mutated antithrombins. 
     In one other particular embodiment, the invention relates to the use as mentioned above, wherein said mutated antithrombin further comprises at least one mutation at the glycosylation sites at the amino acid at position 96, 135, 155 or 192, in particular at position 135, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2. 
     Glysosylation sites are necessary for antithrombin secretion when antithrombin is expressed in eukaryotic cells. However, removing one site does not impair antithrombin secretion while increases heparin-like glycosaminoglycans binding. Indeed, glycosylation chains are involved in antithrombin-cellular heparin-like glycosaminoglycans binding. 
     The interaction with cellular heparin-like glycosaminoglycans enhances the cytoprotective effect of anthithrombin, and mutatis mutandis, the cytoprotective activity of mutated antithrombin according to the invention. 
     An advantageous embodiment of the invention relates to the use of a composition comprising at least a mutated antithrombin having an anticoagulant activity substantially reduced with respect to the anticoagulant activity of the non mutated antithrombin, or having substantially no anticoagulant activity,
         said mutated antithrombin having further:
           a thrombin inhibitory activity substantially reduced, or substantially lost, or   a factor Xa inhibitory activity reduced, or substantially lost, or   a thrombin inhibitory activity and a factor Xa inhibitory activity substantially reduced, or substantially lost,   
           and said mutated antithrombin comprising at least one mutation:
           within the region from the amino acid at position 380 to the amino acid at position 400, in particular at positions 393 or 394, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2, or   within the region from the amino acid at position 412 to the amino acid at position 432, in particular at position 425 or 426, the amino acid numbering referring to the antithrombin amino acid sequence comprising the signal peptide, represented by SEQ ID NO: 26,   
           said mutation being a substitution, insertion or deletion,       

     for the preparation of a drug intended for the prevention or the treatment of pathologies associated with infection, inflammation or hypoxic injury, in particular sepsis and ischemia/reperfusion related to stroke, ischemia/reperfusion related to surgery and ischemia/reperfusion related to organ transplantation. 
     A preferred embodiment of the invention relates to the use above mentioned, wherein said mutated antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:4, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 393, by an Histidine (His),   SEQ ID NO:6, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the insertion of a Proline (Pro) between the amino acid at position 393 and the amino acid at position 394,   SEQ ID NO:8, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393,   SEQ ID NO:10, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 394,   SEQ ID NO:62, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, and the substitution of the amino acid at position 394 by a Glutamine (Gln), and   SEQ ID NO:64, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, and the substitution of the amino acid at position 394 by a Glutamic acid (Glu).       

     Another preferred embodiment of the invention relates to the above defined use, wherein said mutated antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:14, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 393, by an Histidine (His), and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:16, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the insertion of a Proline (Pro) between the amino acid at position 393 and the amino acid at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:18, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and at position 394,   SEQ ID NO:20, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:22, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 394 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:24, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:66, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamine (Gln), and the substitution of the amino acid at position 135, by a Glutamine (Gln), and   SEQ ID NO:68, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamic acid (Glu) and the substitution of the amino acid at position 135, by a Glutamine (Gln).       

     Another preferred embodiment of the invention related to the above mentioned use, wherein said mutated antithrombin comprises at least one mutation within the region from the amino acid at position 412 to the amino acid at position 432, particularly within the region from the amino acid at position 412 to the amino acid at position 429, particularly within the region from the amino acid at position 422 to the amino acid at position 426, in particular at position 425 or 426, the amino acid numbering referring to the antithrombin amino acid sequence comprising the signal peptide, represented by SEQ ID NO: 26, said mutation being a substitution, insertion or deletion. 
     The mutated antithrombins of the invention can comprise others mutations, outside of the region from the amino acid at position 412 to the amino acid at position 432, provided there is no change in the above-mentioned properties of the mutated antithrombins. 
     In a preferred embodiment, the invention relates to the use as mentioned herein, wherein said mutated antithrombin further comprises at least one mutation at the glycosylation sites at the amino acid at position 128, 167, 187 or 224, in particular at position 167 the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 26. 
     A more preferred embodiment of the invention relates to the above mentioned use, wherein said mutated antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:28, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 425, by an Histidine (His), or   SEQ ID NO:30, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the insertion of a Proline (Pro) between the amino acid at position 425 and the amino acid at position 426, or   SEQ ID NO:32, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425, or   SEQ ID NO:34, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 426,   SEQ ID NO:70, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, and the substitution of the amino acid at position 426 by a Glutamine (Gln), and   SEQ ID NO:72, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO: 26, and the substitution of the amino acid at position 426 by a Glutamic acid (Glu).       

     Another preferred embodiment of the invention relates to the use mentioned above, wherein said mutated antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:38, said amino acid sequence comprising in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 425, by an Histidine (His), and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:40, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the insertion of a Proline (Pro) between the amino acid at position 425 and the amino acid at position 426, and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:42, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and at position 426,   SEQ ID NO:44, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:46, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:48, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:74, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamine (Gln), and the substitution of the amino acid at position 167, by a Glutamine (Gln), and   SEQ ID NO:76, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamic acid (Glu) and the substitution of the amino acid at position 167, by a Glutamine (Gln).       

     The invention also relates to the use of a combination comprising
         a first antithrombin consisting of at least one mutated antithrombin having a substantially reduced anticoagulant activity, or substantially no anticoagulant activity according herein, and   a second antithrombin consisting of at least an antithrombin, having an anticoagulant activity similar to that of the wild type antithrombin       

     as a combination product for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury, said combination product being possibly used for a simultaneous, sequential or separate administration, 
     said first and said second antithrombins being in a predetermined weight ratio, preferably in a respective weight ratio of about 9:1 to about 1:4, preferably from about 4:1 to about 1:2, more preferably from about 2:1 to about 1:2. 
     According to the invention, the terms “a first antithrombin consisting of at least one mutated antithrombin” refer to the mutated antithrombin as mentioned above. 
     According to the invention, the terms “a second antithrombin consisting of at least an antithrombin, having an anticoagulant activity similar to that of the wild type antithrombin” refer to any anthithrombin having no mutation and corresponding to wild type antithrobin, or antithrombin having at least one mutation, said mutation not affecting the anticoagulant activity of said second antithrombin. 
     Thus, the second antithrombin of the invention may have a mutation in one or more glycosylation site, in particular a mutation in the residue at the position 135 of the sequence SEQ ID NO 2 or in the residue at position 167 of the SEQ ID NO 26. These “mutated antithrombin” (a second antithrombin) retain their anticoagulant activity. 
     Since heparin may compete with the interaction between mutated antithrombin and cellular heparin-like glycosaminoglycans, the mutated antithrombin according to the invention is preferably not administered in patients that have received heparin treatment. Other anticoagulant can be used in association with the mutated antithrombin of the invention provided that said association does not impair the cytoprotective activity of mutated antithrombin. 
     The combination of the first antithrombin and the second antithrombin according to the invention is administered at a dosage from about 20 UI/kg/day to about 600 UI/kg/day, preferably from about 40 UI/kg/day to about 300 UI/kg/day. 
     In a case of a ratio first/second antithrombin corresponding to a ratio 9/1, said first antithrombin is administered at a dosage of from about 36 IU/kg/day to about 270 IU/kg/day and said second antithrombin is administered at a dosage of from about 4 IU/kg/day to about 30 IU/kg/day. 
     Also, the combination of said first and second antithrombin according to the invention can be administered in a patient in a need thereof at a concentration from about 0.5 to about 15 UI/ml, particularly from about 1 to about 7.5 UI/ml to reach about 100% to 750% of AT in plasma. The invention also relates to a method for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury, comprising the administering in a patient in a need thereof of a combination comprising:
         a first antithrombin consisting of at least one mutated antithrombin having a substantially reduced anticoagulant activity, or substantially no anticoagulant activity according herein, and   a second antithrombin consisting of at least an antithrombin, having an anticoagulant activity similar to that of the wild type antithrombin       

     said combination being administered at a dosage from about 20 UI/kg/day to about 600 UI/kg/day, preferably from about 40 UI/kg/day to about 300 UI/kg/day. 
     The combination according to the invention confers a cytoprotective activity against cellular injury via both first antithrombin while presence of the second antithrombin reduces the hemorrhagic accident. 
     In a preferred embodiment, the invention relates to the use of a combination as mentioned above, as a combination product for the for the preparation of a drug intended for the treatment or prevention of pathologies related to cellular ischemia/reperfusion injury, in particular selected from the group comprising: Inflammatory syndromes, Cardiovascular diseases, Neural or Brain diseases, Ischemia/reperfusion injury related to surgery, and Ischemia/reperfusion injury related to organ transplantation, or for the treatment or prevention of pathologies related to infections, in particular selected from the group comprising: Infectious diseases, and Inflammation associated diseases. 
     A preferred embodiment of the invention relates to the use of a combination above defined, wherein said pathologies are selected from the group comprising sepsis, ischemic stroke, acute myocardial infarction, extremity ischemia acute neurodegenerative disease, chronic neurodegenerative disease, such as Alzheimer&#39;s disease, Down syndrome, Huntington&#39;s disease, and Parkinson&#39;s disease, organ transplantation, chemotherapy, and radiation injury, such as brain radiation injury. 
     In one preferred embodiment, the present invention relates to the use a composition as defined above for the preparation of a drug/medicine intended for the prevention or the treatment of sepsis; i.e. systemic inflammatory response syndrome (SIRS) accompanying an infective disease. Examples of syndromes caused by the aggravation of sepsis include severe sepsis, septic shock, and multiple organ dysfunction syndromes. 
     In one particular embodiment, the invention relates to the use of a combination mentioned above, wherein said mutated antithrombin has:
         a thrombin inhibitory activity substantially reduced, or substantially lost, or   a factor Xa inhibitory activity reduced, or substantially lost, or   a thrombin inhibitory activity and a factor Xa inhibitory activity substantially reduced, or substantially lost.       

     A more particular embodiment of the invention relates to the use of a combination above-mentioned, wherein said first antithrombin comprises at least one mutation within the region from the amino acid at position 380 to the amino acid at position 400, particularly within the region from the amino acid at position 390 to the amino acid at position 397, particularly within the region from the amino acid at position 390 to the amino acid at position 394, in particular at positions 393 or 394, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2, said mutation being a substitution, insertion or deletion, 
     and wherein said second antithrombin is the wild type antithrombin. 
     In an advantageous embodiment, the present invention relates to the use such as defined above, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:4, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 393, by an Histidine (His),   SEQ ID NO:6, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the insertion of a Proline (Pro) between the amino acid at position 393 and the amino acid at position 394,   SEQ ID NO:8, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393,   SEQ ID NO:10, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 394,   SEQ ID NO:18, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and at position 394,   SEQ ID NO:62, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, and the substitution of the amino acid at position 394 by a Glutamine (Gln), and   SEQ ID NO:64, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, and the substitution of the amino acid at position 394 by a Glutamic acid (Glu),       

     and said second antithrombin consists of SEQ ID NO:2. 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, in association with the wild type antithrombin. 
     In an advantageous embodiment, the present invention relates to the use of a composition In such as defined above, wherein said first antithrombin further comprises at least one mutation at the glycosylation sites at the amino acid at position 96, 135, 155 or 192, in particular at position 135, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2. 
     Another advantageous embodiment of the present invention relates to the use such as defined above, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:14, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 393, by an Histidine (His), and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:16, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the insertion of a Proline (Pro) between the amino acid at position 393 and the amino acid at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:20, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:22, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 394 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:24, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:66, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamine (Gln), and the substitution of the amino acid at position 135, by a Glutamine (Gln), and   SEQ ID NO:68, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamic acid (Glu) and the substitution of the amino acid at position 135, by a Glutamine (Gln),       

     and said second antithrombin consists of SEQ ID NO:2. 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, and a mutation at a glycosylation site, in association with the wild type antithrombin. 
     In another preferred embodiment, the invention relates to the use of a composition as defined above, wherein said second antithrombin comprises at least one mutation at the glycosylation sites at the amino acid at position 96, 135, 155 or 192, in particular at position 135, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 2. 
     In another preferred embodiment, the invention relates to the use such as defined above, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:14, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 393, by an Histidine (His), and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:16, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the insertion of a Proline (Pro) between the amino acid at position 393 and the amino acid at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:20, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:22, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 394 and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:24, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the deletion of the amino acid at position 393 and at position 394, and the substitution of the amino acid at position 135, by a Glutamine (Gln),   SEQ ID NO:66, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamine (Gln), and the substitution of the amino acid at position 135, by a Glutamine (Gln), and   SEQ ID NO:68, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394 by a Glutamic acid (Glu) and the substitution of the amino acid at position 135, by a Glutamine (Gln),       

     and said second antithrombin consists of the amino acid sequence SEQ ID NO:78, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 135, by a Glutamine (Gln). 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, and a mutation at a glycosylation site, in association with a second antithrombin having a mutation in a glycosylation site, but retaining its anticoagulant activity. 
     In one other particular embodiment, the invention discloses the use such as defined above, wherein said first antithrombin comprises at least one mutation within the region from the amino acid at position 412 to the amino acid at position 432, particularly within the region from the amino acid at position 412 to the amino acid at position 429, particularly within the region from the amino acid at position 422 to the amino acid at position 426, in particular at position 425 or 426, the amino acid numbering referring to the antithrombin amino acid sequence comprising the signal peptide, represented by SEQ ID NO: 26, said mutation being a substitution, insertion or deletion, 
     and wherein said second antithrombin is the wild type antithrombin. 
     Another preferred embodiment of the invention relates to the use such as defined above, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:28, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 425, by an Histidine (His), or   SEQ ID NO:30, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the insertion of a Proline (Pro) between the amino acid at position 425 and the amino acid at position 426, or   SEQ ID NO:32, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425, or   SEQ ID NO:34, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 426,   SEQ ID NO:42, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and at position 426,   SEQ ID NO:70, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, and the substitution of the amino acid at position 426 by a Glutamine (Gln), and   SEQ ID NO:72, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, and the substitution of the amino acid at position 426 by a Glutamic acid (Glu),       

     and second antithrombin consists of SEQ ID NO:26. 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, in association with the wild type antithrombin. 
     Also, in another preferred embodiment, the invention relates to the use such as defined above, wherein said first antithrombin further comprises at least one mutation at the glycosylation sites at the amino acid at position 128, 167, 187 or 224, in particular at position 167, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 26. 
     Another preferred embodiment of the invention relates to the use as previously defined, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:38, said amino acid sequence comprising in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 425, by an Histidine (His), and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:40, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the insertion of a Proline (Pro) between the amino acid at position 425 and the amino acid at position 426, and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:44, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:46, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:48, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:74, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamine (Gln), and the substitution of the amino acid at position 167, by a Glutamine (Gln), and   SEQ ID NO:76, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamic acid (Glu) and the substitution of the amino acid at position 167, by a Glutamine (Gln),       

     and second antithrombin consists of SEQ ID NO:26. 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, and a mutation at a glycosylation site, in association with the wild type antithrombin. 
     Another preferred embodiment of the invention relates to the use such as defined above, wherein said second antithrombin comprises at least one mutation at the glycosylation sites at the amino acid at position 128, 167, 187 or 224, in particular at position 167, the amino acid numbering referring to the antithrombin amino acid sequence represented by SEQ ID NO: 26. 
     Another preferred embodiment of the invention relates to the use such as defined above, wherein said first antithrombin is an amino acid sequence selected from the group consisting of:
         SEQ ID NO:38, said amino acid sequence comprising in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 425, by an Histidine (His), and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:40, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the insertion of a Proline (Pro) between the amino acid at position 425 and the amino acid at position 426, and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:44, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:46, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:48, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the deletion of the amino acid at position 425 and at position 426 and the substitution of the amino acid at position 167, by a Glutamine (Gln),   SEQ ID NO:74, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamine (Gln), and the substitution of the amino acid at position 167, by a Glutamine (Gln), and   SEQ ID NO:76, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426 by a Glutamic acid (Glu) and the substitution of the amino acid at position 167, by a Glutamine (Gln),       

     and second antithrombin consists of the amino acid sequence SEQ ID NO:80, said amino acid sequence comprising, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 167, by a Glutamine (Gln). 
     The above mentioned combination contains at least one mutated first antithrombin having one or two mutations in the “reactive center loop” of antithrombin, and a mutation at a glycosylation site, in association with a second antithrombin having a mutation in a glycosylation site, but retaining its anticoagulant activity. 
     The invention also relates to a composition comprising at least
         a first antithrombin consisting of at least one mutated antithrombin having a substantially reduced anticoagulant activity, or substantially no anticoagulant activity according to any of claim  1  to  5  or  9 , and   a second antithrombin consisting of at least an antithrombin, having an anticoagulant activity similar to that of the wild type antithrombin       

     as a combination product for the preparation of a drug intended for the prevention or the treatment of pathologies associated with cellular injury, such as infection, inflammation or hypoxic injury., said combination product being possibly used for a simultaneous, sequential or separate administration, 
     said first and said second antithrombins being in a predetermined weight ratio being in a predetermined weight ratio, preferably in a respective weight ratio of about 10:1 to about 1:5, preferably from about 5:1 to about 1:2, more preferably from about 2:1 to about 1:2. 
     In one preferred embodiment, the invention discloses a combination such as defined above, as a combination product for the preparation of a drug intended for the treatment or prevention of pathologies related to cellular ischemia/reperfusion injury, in particular selected from the group comprising: Inflammatory syndromes, Cardiovascular diseases, Neural or Brain diseases. Ischemia/reperfusion injury related to surgery, and Ischemia/reperfusion injury related to organ transplantation, or for the treatment or prevention of pathologies related to infections, in particular selected from the group comprising: infectious diseases, and inflammation associated diseases. 
     In another preferred embodiment, the invention relates to a combination above defined, wherein said pathologies are selected from the group comprising: sepsis, ischemic stroke, acute myocardial infarction, extremity ischemia, acute neurodegenerative disease, chronic neurodegenerative disease, such as Alzheimer&#39;s disease, Down syndrome, Huntington&#39;s disease, and Parkinson&#39;s disease, organ transplantation, chemotherapy, and radiation injury, such as brain radiation injury. 
     In other specific embodiment, the invention relates to a combination as defined above, wherein said first antithrombin has:
         a thrombin inhibitory activity substantially reduced, or substantially lost, or   a factor Xa inhibitory activity reduced, or substantially lost, or   a thrombin inhibitory activity and a factor Xa inhibitory activity substantially reduced, or substantially lost.       

     Another preferred embodiment of the invention relates to a combination such as previously defined, wherein said first antithrombin is an amino acid sequence selected from the group consisting of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:18, SEQ ID NO: 62, and SEQ ID NO: 64, and said second antithrombin consists of SEQ ID NO:2. 
     In one other particular embodiment the invention relates to a combination such as previously defined, wherein said first antithrombin is an amino acid sequence selected from the group consisting of: SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:66, and SEQ ID NO:68, and said second antithrombin consists of SEQ ID NO: 2 or SEQ ID NO:78. 
     Also, in another preferred embodiment, the invention relates to a combination according to the above definition, wherein said first antithrombin is chosen from the group consisting of: SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:42, SEQ ID NO:70, and SEQ ID NO:72, and said second antithrombin consists of SEQ ID NO:26. 
     In one other particular embodiment the invention relates to a combination such as previously defined, wherein said first antithrombin is chosen from the group consisting of: SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48, SEQ ID NO:74, and SEQ ID NO:76, and said second antithrombin consists of SEQ ID NO:26 or SEQ ID NO:80. 
     The invention also relates to a pharmaceutical composition comprising as active ingredient at least a mutated antithrombin, as defined above, in association with a pharmaceutically acceptable vehicle, in particular a mutated antithrombin of SEQ ID NO: 62, SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74 and SEQ ID NO: 76. 
     By the expression “pharmaceutically acceptable vehicle”, one means pharmaceutically acceptable solid or liquid, diluting or encapsulating, filling or carrying agents, which are usually employed in pharmaceutical industry for making pharmaceutical compositions. 
     The dosage forms of the pharmaceutical composition includes immediate release, extended release, pulse release, variable release, controlled release, timed release, sustained release, delayed release, long acting, and combinations thereof. 
     Preferably, the pharmaceutical composition according to the invention can be, intravenously, intraperitonealy, subcutaneously or orally delivered. 
     In one other preferred embodiment, the invention relates to a pharmaceutical composition as mentioned above, said pharmaceutical composition being preferably administered at a dosage from about 80 IU/kg/day to about 300 IU/kg/day, preferably from about 100 IU/kg/day to about 200 IU/kg/day. 
     The invention also relates to a pharmaceutical composition, comprising as active ingredient a combination of the group comprising:
         of at least a first antithrombine consisting of one mutated antithrombin having a substantially reduced anticoagulant activity, or substantially no anticoagulant activity such as defined above, and   at least a second antithrombine consisting of at least an antithrombin, having an anticoagulant activity similar to that of the wild type antithrombin       

     of the group consisting of:
         SEQ ID NO: 4; SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10, SEQ ID NO: 18 SEQ ID NO: 62 or SEQ ID NO: 64, in association with SEQ ID NO 2,   SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 66 or SEQ ID NO: 68, in association with SEQ ID NO 2,   SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 66 or SEQ ID NO: 68, in association with SEQ ID NO 78,   SEQ ID NO: 28, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 42; SEQ ID NO: 70 or SEQ ID NO: 72, in association with SEQ ID NO 26,   SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 74 or SEQ ID NO: 76, in association with SEQ ID NO 26, and   SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 74 or SEQ ID NO: 76, in association with SEQ ID NO 80,       

     in association with a pharmaceutically acceptable vehicle. 
     Preferably, the pharmaceutical composition according to the invention can be, intravenously, intraperitonealy, subcutaneously or orally delivered. 
     In one other preferred embodiment, the invention relates to a pharmaceutical composition as mentioned above, said pharmaceutical composition being preferably administered at a dosage from about 20 UI/kg/day to about 600 UI/kg/day, preferably from about 40 UI/kg/day to about 300 UI/kg/day. 
     The invention also relates to a mutated antithrombin, which contains at least an amino acid substitution of the amino acid at position 394 of SEQ ID NO:2 by a glutamic acid (Glu) or a Glutamine (Gln), and in particular mutated antithrombin represented by SEQ ID NO: 62 or SEQ ID NO 64. 
     The invention also relates to a mutated antithrombin, which contains at least two mutations:
         the first mutation being, in the sequence of antithrombin represented by SEQ ID NO:2, the substitution of the amino acid at position 394, by glutamic acid (Glu) or a Glutamine (Gln), and   the second mutation being the substitution of the amino acid at position 135, by a Glutamine (Gln),       

     said mutated antithrombin being in particular represented by SEQ ID NO: 66 or 68. 
     The invention also relates to a mutated antithrombin, which contains at least an amino acid substitution of the amino acid at position 426 of SEQ ID NO:26 by a glutamic acid (Glu) or a Glutamine (Gln), and in particular mutated antithrombin represented by SEQ ID NO: 70 or SEQ ID NO:72. 
     The invention also relates to a mutated antithrombin, which contains at least two mutations:
         the first mutation being, in the sequence of antithrombin represented by SEQ ID NO:26, the substitution of the amino acid at position 426, by glutamic acid (Glu) or a Glutamine (Gln), and   the second mutation being the substitution of the amino acid at position 167, by a Glutamine (Gln),       

     said mutated antithrombin being in particular represented by SEQ ID NO: 74 or 76. 
     The invention also relates to a nucleotide sequence coding for a mutated antithrombin as defined abovesaid nucleic acid sequence being a DNA or an RNA, in particular nucleotide sequences chosen in the group consisting of SEQ ID NO: 61, SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73 and SEQ ID NO: 75, or a complementary sequence of said nucleic acid sequence. 
     The invention is illustrated, but not limited to, by the following example and the following figures. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1 : preparation of shuttle vector carrying full length antithrombin cDNA. 
       2 μg of pENTR vector containing truncated AT cDNA (lane 1 and 2), pCMV6 vector containing full length AT cDNA (lane 3 and 4) or shuttle vector pENTR-AT (lane 5 and 6) are loaded on 1% agarose gel before (lane 1, 3, 5) or after (lane 2, 4, 6) complete digestion by both SacII and StuI. Molecular weight standard sizes are inducated on the left hand of the figure and expressed in base pair (bp). SacII/StuI digestion of pCMV6 vector containing full length AT cDNA releases a 1182 by band corresponding to full length AT cDNA cloned into pENTR vector isolated from SacII/StuI digestion of pENTR vector containing truncated AT cDNA. After ligation of these two fragments the final product is effectively recircularized and shows the expected profile for pENTR-AT after SacII/StuI digestion. 
         FIG. 2 : Characterization of the AT expression vector. 
       2 μg of pCDNA 3.2 vector (lane 1, 2, 3), pCDNA 3.2 vector containing full length AT cDNA (lane 4, 5, 6) or pCDNA 3.2 vector containing full length AT-N135Q-Pro394 cDNA (lane 7, 8, 9) are loaded on 1% agarose gel before endonucleases treatment (lane 1, 4, 7), after cleavage by StuI (lane 2, 5, 8), or after complete cleavage by both SacII and StuI (lane 3, 6, 9). Molecular weight standard sizes are indicated on the right hand of the figure and expressed in base pair (bp). There is one SacII and one StuI cleavage site in pCDNA 3.2 vector at position 3189 and 4329 respectively. Therefore cleavage of pCDNA 3.2 by StuI only leads to linearization of the vector (7711 bp band) whereas cleavage of pCDNA 3.2 by both StuI and SacII cuts the vector in two fragments (6571 bp and 1140 bp). Substitution of 912-3174 fragment by AT cDNA fragment (1448 bp) into pCDNA 3.2 by recombination introduces one more SacII site at position 1070 and one more StuI site at position 2252 into pcDNA-AT. Then cleavage of pCDNA-AT by StuI gives two fragments (5634 bp and 1263 bp) and cleavage by both endonucleases gives 4 fragments (4452 bp, 1182 bp, 1140 and 123 bp). The same is true for -N135Q-Pro394 cDNA. 
         FIG. 3 : Clone screening for secretion of recombinant AT in cell culture media. 
       For each clone isolated after transfection with pCDNA-AT (clone 1 to 5 in lane 1 to 5, respectively), pCDNA-AT-N135Q (clone 1 to 4 in lane 6 to 9, respectively), or with pCDNA-AT-N135Q-Pro394 (clone 1 to 5 in lane 10 to 14, respectively), 30 μl of conditioned media harvested after 24 hours contact with cells are analysed by western-blotting in denaturing condition for their ability to secrete full length recombinant antithrombin. For each clone a single band of variable intensity corresponding to recombinant antithrombin can be seen. Recombinant wild type antithrombin migrate at the same level than control antithrombin purified from plasma (lane 15, 150 ng/lane) and expression level is estimated around 2 mg/L according to band intensity measurement. For wt-AT, clone 4 is chosen for expansion into cell factory, since the level of expression seems to be slightly higher than the others. Mutant AT-N135Q and AT-N135Q-Pro394 migrate just below control antithrombin purified from plasma (lane 15) confirming the loss of a glycosylation site due to substitution N135Q. The stable expression clones selected for large scale protein production are clones 1 for both AT-N135Q and AT-N135Q-Pro394. 
         FIG. 4 : Integrity and purity of recombinant antithrombin. 
       To verify integrity and purity of recombinant antithrombin after heparin affinity purification and ion exchange concentration, 2 μg of AT-N135Q-R393H (lane 1), AT-N135Q-Pro394 (lane 2) or control plasma antithrombin (lane 3) are analyzed by SDS-PAGE followed by coomassie staining. As expected, the two mutated antithrombins migrate at molecular weight slightly lower than plasma antithrombin because of loss of a glycosylation site (substitution N135Q) and they show a single band pattern with band intensity corresponding to quantity loaded on the gel (based on absorbance estimation). Then recombinant antithrombin appears pure and can be tested for its anticoagulant properties and affinity for heparin derivatives. Molecular weight standard sizes are presented on the right hand of the figure and expressed in kiloDalton (KD). 
         FIG. 5 : Anti-factor Xa activity of plasmatic or mutated antithrombins at saturating pentasaccharide concentration. 
         FIG. 5A : Plasma AT (black square: 80 nM, hollow square: 40 nM, Black circle: 20 nM, hollow circle: 10 nM) is tested for its ability to inhibit chromogenic substrate S2765 (200 μM) hydrolysis by FXa (1 nM) in the presence of pentasaccharide (1 μM or 1.73 mg/L) in continuous assay. Time expressed in second is plotted in abscissa; absorbence at 405 nm is plotted in ordinate. substrate hydrolysis curves are fitted using equation 3 to determine the kinetic rate constant (k), (gray lines) 
         FIG. 5B : Kinetic rate constant (k) determined in  FIG. 5  a is thus plotted as the function of AT concentration and fitted using equation 4 to determine inhibition rate constant kon. The plasma antithrombin concentration (nM) is plotted in abscissa; the kinetic rate constante (k) expressed in s −1  is plotted in ordinate. 
         FIG. 6 : AT-N135Q-R393H and AT-N135Q-Pro394 are tested for their ability to inhibit FXa activity in discontinuous assay. In a first time AT-N135Q-R393H (black square: 200 nM) or AT-N135Q-Pro394 (hollow square: 2.5 μM) are incubated with FXa (20 nM) in the presence of pentasaccharide (10 μM or 17.3 mg/L) over a period of time from 0 to 120 min (for AT-N135Q-R393H) or from 0 to 1400 min (for AT-N135Q-Pro394). In a second time FXa residual activity is measured by adding 190 μl of 52765 (200 μM) to 10 μl of previous mixture. Initial rate of substrate hydrolysis is then plotted as the function of incubation time with inhibitor and curves are fitted with equation 1 to determine kon (gray lines). Time expressed in minute is plotted in abscissa; substrate hydrolysis rate expressed in OD/s −1  is plotted in ordinate. 
         FIG. 7 : AT-Pro394 is tested for its ability to inhibit IL6 production by LPS stimulated blood cells. 
       Blood is pre-treated for 5 minutes at 37° C. with either PBS (white box), either AT-wt (Aclotine®, final concentration of 1.6 IU/ml, black box) or AT-Pro394 (final concentration of 1.6 IU/ml, gray box), and then exposed to 16 hours stimulation with 10 or 100 μg/mL LPS. Blood is then centrifugated at 2300 g for 10 minutes at 12° C. and IL6 protein levels from plasma supernatants are measured quantitatively. Plasma IL6 concentration expressed in percentage is plotted in ordinate (100% corresponds to the IL6 level of the PBS control). The experience was performed with the blood of 2 different healthy subjects. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     Experimental Part 
     In order to produce a mutated antithrombin having lost or reduced anticoagulant activity, in particular factor Xa and IIa inhibitory activity, and able to bind to heparin and to the pentasaccharide, differents types of mutations have been contemplated and particularly, mutations within the reactive center loop (region from the amino acid 380 to amino acid 400), mutations within an exosite region remote from the loop accessible for proteinase interaction (Chuang Y J, Swanson R, Raja S M, Olson S T. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin  J Biol Chem.  2001; 276:14961-71) and mutations within a consensus sequence of glycosylation (amino acids 135 to 137 and 155 to 157) (Fan B, Crews B C, Turko I V, Choay J, Zettlmeissl G, Gettins P. Heterogeneity of recombinant human antithrombin III expressed in baby hamster kidney cells. Effect of glycosylation differences on heparin binding and structure  J Biol Chem.  1993; 268:17588-96). 
     Several mutations have been carried out to obtain mutated antithrombins, and in particular: 
     deletion within the reactive loop of the antithrombin, in the region P4-P4′ (Ala 391-Asn 396) in order to eliminate antithrombin inhibitory activity toward any coagulant proteases such as FXa and FIIa, 
     substitution of amino acids within the region P4-P4′ (Ala 391-Asn 396) of the reactive loop, and in particular the substitution of the amino acid at position 393 (Arg) by an Histidine, or the substitution of the amino acid at position 394 (Ser) by a Glutamic acid or by a Glutamine. 
     insertion of a Proline between the amino acid at position 393 and the amino acid at position 394, and 
     substitution of amino acids within the region of glycosylation of the antithrombin, and in particular the substitution of the amino acid at position 135 (Asp) by a Glutamine, in order to increase the affinity with heparin and pentasaccharide. 
     Material and Methods 
     I/ Preparation of Mutated Antithrombins 
     Preparation of Shuttle Vector pENTR Carrying Full Length Antithrombin cDNA (pENTR-AT): 
     The antithrombin cDNA sequence initially cloned into pENTR vector (Invitrogen, HORF clone reference IOH14497) is found to be truncated and has to be replaced by the full length antithrombin sequence, cloned into pCMV6 (Origene, reference TC110831). The plasmid pCMV6 containing full length antithrombin cDNA is digested by both SacII and StuI endonucleases. The 1182 base pairs fragment is isolated on 1% agarose gel and purified using the QIAquick Gel Extraction Kit. This 1182 base pairs fragment, corresponding to the SacII-StuI fragment of antithrombin cDNA, is ligated into pENTR vector (2760 bp) also linearized by SacII and StuI and recover as described above. Result of this cassette exchange is verified by electrophoresis on 1% agarose gel ( FIG. 1 ) and sequencing. 
     Mutagenesis on Antithrombin cDNA: 
     The resulting plasmid pENTR carrying cDNA encoding for wild type antithrombin (pENTR-ATwt) is used as a template for further mutagenesis by PCR using the QuickChange II Site-Directed Mutagenesis Kit according to the manufacturer recommendations (Stratagene). The wild type antithrombin has the same amino acid sequence as the plasma antithrombin but is produced under a recombinant form. Mutagenic primers (table 1) are used to introduce a codon for Glutamine in place of codon for Arginine 135 (N135Q) for production of plasmid pENTR-AT-N135Q. Single amino acid substitution of Arginine 393 by an Histidine (R393H), single amino acid substitution of Serine 394 by a Glutamic acid (S394Q) or by a Glutamine (S394E), insertion of a Proline between Arginine 393 and Serine 394 (Pro394), or deletion of Arginine 393 (ΔR393), Serine 394 (ΔS394) or both Arginine 393 and Serine 394 (ΔR393S394) are introduced by PCR using the QuickChange II Site-Directed Mutagenesis Kit with pENTR-ATwt as template and mutagenic primers as described in table 1. The same couples of mutagenic primers are used in PCR reaction with pENTR-AT-N135Q as template to prepare plasmids carrying cDNA encoding for double-mutant and triple-mutant antithrombin N135Q-R393H, N135Q-S394Q, N135Q-S394E, N135Q-Pro394, N135Q-ΔR393, N135Q-ΔA394, N135Q-ΔR393S394 respectively. Then the integrity of each variant cassette that is to say cDNA encoding for the double-mutant or triple-mutant antithrombin above mentioned is established by DNA sequencing. 
     Cassette Exchange Between Shuttle Vector and Expression Vector: 
     All the cDNAs described above encoding for antithrombin, single antithrombin mutants or double antithrombin mutants are transferred from shuttle vector pENTR into eucaryote expression vector pCDNA 3.2 by recombination using Gateway LR Clonase II Enzyme Mix (“Gateway Technology” developed by Invitrogen). The final expression constructs are verified by electrophoresis on 1% agarose gel and sequencing again before transfection ( FIG. 2 ). 
     Transfection of Eucaryote Cells and Protein Production: 
     Plasmid constructs resulting of previous recombination named pCDNA-ATwt, pCDNA-AT-N135Q, pCDNA-AT-R393H, pCDNA-AT-S394Q, pCDNA-AT-S394E, pCDNA-AT-Pro394, pCDNA-AT-ΔR393, pCDNA-AT-ΔS394, pCDNA-AT-ΔR393S394, pCDNA-AT-N135Q-R393H, pCDNA-AT-N135Q-S394Q pCDNA-AT-N135Q-S394E pCDNA-AT-N135Q-Pro394, pCDNA-AT-N135Q-ΔR393, pCDNA-AT-N135Q-ΔS394 and pCDNA-AT-N135Q-ΔR393S394, respectively are used for transfection of modified human embryonic kidney cells (HEK-293) or baby hamster kidney cells (BHK-21). Cells are grown in “Dulbeco&#39;s Modified Eagle&#39;s Medium/F-12” containing 2 mM L-Glutamine, 100 U/ml penicillin, 100 μg/ml Streptomycin and 5% foetal bovine serum (Invitrogen) and approximately 10 6  cells are transfected with 20 μg of DNA by calcium-phosphate coprecpitation (Sambrook et al. Molecular cloning: A laboratory manual, 2 nd  edition, page 16.33). The stable expression cell lines are selected by G418 (during clones selection, G418 concentration is 0.8 mg/ml in cell culture media and then decreased to 0.4 mg/ml to maintain selection pressure during clones amplification) and screened for antithrombin secretion by ELISA, using mouse monoclonal antibody anti antithrombin as capture antibody and Horse Radish Peroxydase conjugate sheep polyclonal antibody anti antithrombin as detecting antibody (Antithrombine BioAssay™ ELISA Kit (EUROMEDEX)). The integrity of secreted antithrombin is established by western blotting using sheep monoclonal antibody anti antithrombin and Horse Radish Peroxydase conjugate donkey polyclonal antibody anti sheep (The Binding Site, UK) ( FIG. 3 ). For each mutated antithrombin, a single stable expression clone is expanded into “cell factories nunclon” (Nunc) and large scale protein production is conducted with 300 μl/cm 2 , (as recommended by manufacturer, the minimum volume suitable for a 6320 cm 2  culture area cell factory is 2 liters) of &lt;&lt;Dulbeco&#39;s Modified Eagle&#39;s Medium/F-12” containing 2 mM L-Glutamine, 100 U/ml penicillin, 100 μg/ml Streptomycin and 5 μg/ml Insulin/Transferrin/Selenium (Invitrogen). Conditioned media, harvested daily, are centrifuged for 15 min at 3000 g at 4° C., treated with 5 mM benzamidine, 5 mM EDTA and stored at −20° C. 
     Protein Purification: 
     Conditioned media are thawed, pooled, salt concentration adjusted to 0.4 M NaCl and then applied on an heparin immobilized column (Hitrap Heparin 5 ml or Heparin-sepharose CL6B 50 ml, GE Biological) equilibrated with 10 mM Tris, or with 20 mM phosphate buffer, 0.4 M NaCl and 0.1 mM EDTA, pH 7.4. The bound proteins are eluted in the same buffer with a gradient from 0.4 M to 2 M NaCl. The fractions eluted from 0.8 M NaCl and more contained only wild type antithrombin or mutated antithrombins with high heparin affinity. Mutated antithrombins carrying substitution of asparagin 135 by a glutamin (AT-N135, ATN135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, AT-N135Q-ΔR393S394) are eluted from affinity column at higher ionic strength than wild type antithrombin, confirming that destruction of glycosylation site at position 135 increases affinity of antithrombin for heparin (about 90% of mutanted antithrombin carrying substitution N135Q is eluted between 1 and 1.4 M NaCl compared to wild type antithrombin which 90% is eluted between 0.8 and 1.2 M NaCl). The collected fractions are pooled and the salt concentration is decreased either by over night dialysis against 10 mM Tris, or 20 mM phosphate, and 0.1 M NaCl, pH 7.4 at 4° C. or applied on an HiPrep 26/10 desalting column equilibrated with 10 mM Tris, or 20 mM phosphate, and 0.1 M NaCl, pH 7.4. The antithrombin is then concentrated by ion exchange chromatography using a “Resource Q” 1 ml column (GE, Biological) equilibrated with 10 mM Tris, or 20 mM phosphate, and 0.1 M NaCl, pH 7.4 and eluted in the same buffer with a NaCl gradient from 0.1 mM to 0.5 M or 20 mM to 0.5 M. 
     The antithrombin concentration in each elution fraction is estimated by absorbance at 280 nM with an absorption coefficient ε=0.65 g −1 ·l·cm −1  and the integrity of purified wild type antithrombin or mutated antithrombins is tested by western blotting using the same couple of antibodies as described before, and electrophoresis on 10% acrylamide/bisacrylamide gel in native and denaturing conditions followed by coomassie brilliant blue R-250 staining ( FIG. 4 ). Then, the antithrombin preparation is aliquoted and stored at −80° C. before use for functional assay. The same procedure is used to purify plasma antithrombin (used as internal reference) from human plasma. Commercialized AT obtained from human plasma (Aclotine®, LFB, France) was also used as a control in the following experiments. 
     
       
         
               
             
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 oligonucleotides used for the mutated AT constructions 
               
             
          
           
               
                   
                   
                   
                 SEQ ID 
               
               
                 Sens 
                 Mutation 
                 Sequence 
                 NO 
               
               
                   
               
               
                 forward 
                 N135Q 
                 GCCGACTCTATCGAAAAGCCCAGAAATCCTCCAAGTTAGTG 
                 49 
               
               
                   
               
               
                 reverse 
                 N135Q 
                 CACTAACTTGGAGGATTTCTGGGCTTTTCGATAGAGTCGGC 
                 50 
               
               
                   
               
               
                 forward 
                 R393H 
                 GTTGTGATTGCTGGCCATTCGCTAAACCCCAAC 
                 51 
               
               
                   
               
               
                 reverse 
                 R393H 
                 GTTGGGGTTTAGCGAATGGCCAGCAATCACAAC 
                 52 
               
               
                   
               
               
                 forward 
                 S394Q 
                 GTGATTGCTGGCCGTCAGCTAAACCCCAACAGG 
                 81 
               
               
                   
               
               
                 reverse 
                 S394Q 
                 CCTGTTGGGGTTTAGCTGACGGCCAGCAATCAC 
                 82 
               
               
                   
               
               
                 forward 
                 S394E 
                 GTGATTGCTGGCCGTGAGCTAAACCCCAACAGG 
                 83 
               
               
                   
               
               
                 reverse 
                 S394E 
                 CCTGTTGGGGTTTAGCTCACGGCCAGCAATCAC 
                 84 
               
               
                   
               
               
                 forward 
                 Pro394 
                 GTTGTGATTGCTGGCCGTCCATCGCTAAACCCCAAC 
                 53 
               
               
                   
               
               
                 reverse 
                 Pro394 
                 GTTGGGGTTTAGCGATGGACGGCCAGCAATCACAAC 
                 54 
               
               
                   
               
               
                 forward 
                 ΔR393- 
                 GCTGTTGTGATTGCTGGCCTAAACCCCAACAGGGTG 
                 55 
               
               
                   
                 S394 
                   
                   
               
               
                   
               
               
                 reverse 
                 ΔR393- 
                 CACCCTGTTGGGGTTTAGGCCAGCAATCACAACAGC 
                 56 
               
               
                   
                 S394 
                   
                   
               
               
                   
               
               
                 forward 
                 ΔR393 
                 CTGTTGTGATTGCTGGCTCGCTAAACCCCAACAG 
                 57 
               
               
                   
               
               
                 reverse 
                 ΔR393 
                 CTGTTGGGGTTTAGCGAGCCAGCAATCACAACAG 
                 58 
               
               
                   
               
               
                 forward 
                 ΔS394 
                 TGTGATTGCTGGCCGTCTAAACCCCAACAGGG 
                 59 
               
               
                   
               
               
                 reverse 
                 ΔS394 
                 CCCTGTTGGGGTTTAGACGGCCAGCAATCACA 
                 60 
               
               
                   
               
             
          
         
       
     
     II/ In Vitro Characterization of the Mutated Antithrombins 
     Characterization of the mutated antithrombins aims at 
     a) demonstrating that, in a purified system, the following mutated antithrombins: AT-R393H, S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393 and AT-N135Q-ΔS394 exhibit a reduced anti FXa and anti FIIa activity compared with that of wild type antithrombin (AT-wt) in the presence or absence of heparin&#39;s derivatives. 
     b) demonstrating that, the following mutated antithrombins AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, or a composition comprising at least one of these mutated antithrombins and an antithrombin having an anticoagulant activity similar to that of the wild type antithrombin, have, at least, equivalent cytoprotective properties when compared to wild type antithrombin. 
     a) Anti Factor Xa Inhibitory Activity of the Mutated Antithrombins in a Purified System 
     The kinetic assays for antithrombin inhibition of factor Xa (FXa, Kordia) are performed in ‘kinetic’ buffer (Hepes, 20 mM phosphate, pH 7.4, 0.15 M NaCl, 0.1% PEG 8000 and 1 mg/ml bovine serum albumin) in pseudo first order conditions. Briefly, factor Xa is incubated with an excess of tested antithrombins (corresponding to plasma antithrombin, or wild type antithrombin or mutated antithrombins and varying in each assay realized) in the presence or absence of pentasaccharide (Fondaparinux sodique, Arixtra®, GlaxoSmithKline) and the factor Xa residual activity is measured as a function of time. The pentasaccharide is added in excess in the reaction media so that every tested antithrombin is bound to the pentasaccharide. In the absence of pentasaccharide, polybrene (100 μg/ml final) is added in order to neutralize any sulfated glycosaminoglycan that may be present in the reaction media. The residual factor Xa activity is measured as the increase in absorbance at 405 nm resulting from cleavage of the chromogenic substrate (S2765 or S2222, Chromogenix) using a microplate reader (Dynatech MR 5000). The analysis of the data is performed using the GraphPad Prism version 3 software. Absorbance recording is continuous or discontinuous according to the expected inhibition rate constant (kon). 
     The inhibition rate constant (kon) is the second order rate constant given in M −1 ·s −1  which define the velocity of stable complex formation between protease and antithrombin (higher is the kon value, faster will the complex be established). 
     When the expected kon is lower than 10 4  M −1 ·s −1  the discontinuous method is used. Factor Xa (2 to 200 nM) is incubated with tested antithrombins (20 nM to 20 μM) in the presence of pentasaccharide or polybrene in a final volume of 10 μl for 10 seconds to 5 hours, or 10 seconds to 24 hours. At the end of this incubation period, 190 μl of kinetic buffer containing 200 μM substrate is added and absorbance at 405 nm is recorded. 
     The kinetic rate constant (k) is estimated by fitting the substrate hydrolysis initial rate curve to equation (1) using non-linear regression with v0 and v∞ being the substrate hydrolysis rate at time to or t∞ respectively.
 
 vt =( v 0+ v ∞)·exp(− k·t )  (1)
 
     The inhibition rate constant (kon) is calculated from the rate constant (k) using equation (2) where AT is the tested antithrombin concentration.
 
 k=AT·k on  (2)
 
     When the expected kon is higher than 10 4  M −1 ·s −1 , the continuous method is used. The tested antithrombin (1 nM to 1 μM) is incubated with the substrate (200 μM) in the presence of pentasaccharide or polybrene in a final volume of 190 μl and the reaction is started by addition of 10 μL of factor Xa (2 to 200 nM). The rate constant (k) is obtained by fitting the substrate hydrolysis curve to equation (3) or (3′) using non-linear regression analysis where A0 is the absorbance at t0, and vi and vs are respectively the initial and final rates of substrate hydrolysis in the absence of tested antithrombin.
 
 A 405= A 0+ vi ·(1−exp(− k·t ))/ k   (3)
 
     Equation (3′) is also used, particularly in presence of plasma.
 
 A 405= A 0+ vs*t +( vi−vs )*(1−exp(− kt ))/ k  
 
     The inhibition rate constant (kon) is calculated from the kinetic constant (k) using equation (4) that takes into account the competitive effect of the substrate, with S being the initial substrate concentration, Km, the Michaelis constant for factor Xa-substrate interaction, AT the tested antithrombin concentration.
 
 k =( k on/(1+ S/Km ))·[ AT]   (4)
 
     Mutated antithrombins and wild type AT inhibitory activity are measured in the same conditions and compared with plasma AT inhibitory activity. 
     The results with or without pentasaccharide are: 
     wild type antithrombin and AT-N135Q factor Xa inhibitory activity is similar to plasma antithrombin factor Xa inhibitory activity, 
     factor Xa inhibitory activity of the following mutated antithrombins: AT-R393H, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, is negligible compared with wild type antithrombin factor Xa inhibitory activity. 
     factor Xa inhibitory activity of the following mutated antithrombins: AT-S394Q, AT-S394E, AT-N135Q-S394Q and AT-N135Q-S394E, is 2 to 20 fold decreased compared with wild type antithrombin factor Xa inhibitory activity. 
     A decrease in factor Xa inhibitory activity from 2 to 20 fold compared with wild type antithrombin is reached with a composition containing one of the following mutated antithrombins: AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, or AT-N135Q-ΔS394, and AT-wt or AT-N135Q, in a varying ratio. 
     For example, inhibition rate constant (kon) of plasma AT for factor Xa in the presence of saturating amount of pentasaccharide is estimated using continuous method ( FIGS. 5   a  and  5   b ). A value of 2.52×10 5  M −1 ·s −1  is found which is comparable to published values (Olson S T, Björk I, Sheffer R, Craig P A, Shore J D, Choay J.,  J Biol Chem.  1992 June 25; 267 (18): 12528-38, “Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement.) Using this method AT-N135Q-R393H and AT-N135Q-Pro394 are found to be slow factor Xa inhibitors, even in the presence of saturating pentasaccharide concentration. Thus, discontinuous method was performed to evaluate kon values for factor Xa inhibition by AT-N135Q-R393H and AT-N135Q-Pro394 in the presence of pentasaccharide ( FIG. 6 ). AT-N135Q-R393H anticoagulant activity is largely reduced whereas AT-N135Q-Pro394 is almost devoided of anti-factor Xa activity. AT-N135Q-R393H and AT-N135Q-Pro394 kon values are estimated at 4415 M −1 ·s −1  and 33 M −1 ·s −1 , respectively, which is 95 times and at least 7600 times lower than plasma AT. 
     b) Anti Factor IIa Inhibitory Activity of the Mutated Antithrombins in a Purified System. 
     The kinetic assays for antithrombin inhibition of factor IIa (FIIa, Kordia) are performed in ‘kinetic’ buffer (Hepes, 20 mM phosphate, pH 7.4, 0.15 M NaCl, 0.1% PEG 8000 and 1 mg/ml bovine serum albumin) in pseudo first order conditions. Briefly, factor IIa is incubated with an excess of tested antithrombins (corresponding to plasma antithrombin, or wild type antithrombin or mutated antithrombins and varying in each assay realized) in the presence or absence of heparin (heparin sodium, Choay®) and the factor IIa residual activity is measured as a function of time. Heparin is added in excess in the reaction media so that every tested antithrombin is bound to heparin. In the absence of heparin, polybrene (100 μg/ml final) is added in order to neutralize any sulfated glycosaminoglycan that may be present in the reaction media. The residual factor IIa activity is measured as the increase in absorbance at 405 nm resulting from cleavage of the chromogenic substrate (S2238, Chromogenix) using a microplate reader (Dynatech MR 5000). The analysis of the data is performed using the GraphPad Prism version 3 software. Absorbance recording is continuous or discontinuous according to the expected inhibition rate constant (kon). 
     The inhibition rate constant (kon) is the second order rate constante given in M −1 ·s −1  which define the velocity of stable complex formation between protease and antithrombin (higher is the kon value, faster will the complex be established). 
     When the expected kon is lower than 10 4  M −1 ·s −1  the discontinuous method is used. Factor IIa (2 to 200 nM) is incubated with tested antithrombins (20 nM to 20 μM) in the presence of heparin or polybrene in a final volume of 10 μl for 10 seconds to 5 hours, or 10 seconds to 24 hours. At the end of this incubation period, 190 μl of kinetic buffer containing 200 μM substrate is added and absorbance at 405 nm is recorded. 
     The kinetic rate constant (k) is estimated by fitting the substrate hydrolysis initial rate curve to equation (1) using non-linear regression with v0 and v∞ being the substrate hydrolysis rate at time to or t∞ respectively.
 
 vt =( v 0+ v ∞)·exp(− k·t )  (1)
 
     The inhibition rate constant (kon) is calculated from the rate constant (k) using equation (2) where AT is the tested antithrombin concentration.
 
 k=AT·k on  (2)
 
     When the expected kon is higher than 10 4  M −1 ·s −1 , the continuous method is used. The tested antithrombin (1 nM to 1 μM) is incubated with the substrate (200 μM) in the presence of heparin or polybrene in a final volume of 190 μl and the reaction is started by addition of 10 μL of factor IIa (2 to 200 nM). The rate constant (k) is obtained by fitting the substrate hydrolysis curve to equation (3) or (3′) using non-linear regression analysis where A0 is the absorbance at t0, and vi and vs are respectively the initial and final rates of substrate hydrolysis in the absence of tested antithrombin.
 
 A 405= A 0+ vi ·(1−exp(− k·t ))/ k   (3)
 
 A 405= A 0+ vs*t +( vi−vs )*(1−exp(− kt ))/ k   (3′)
 
     The inhibition rate constant (kon) is calculated from the kinetic constant (k) using equation (4) that takes into account the competitive effect of the substrate, with S being the initial substrate concentration, Km, the Michaelis constant for factor IIa-substrate interaction, AT the tested antithrombin concentration.
 
 k =( k on/(1+ S/Km ))·[ AT]   (4)
 
     Mutated antithrombins and wild type AT inhibitory activity are measured in the same conditions and compared with plasma AT inhibitory activity. 
     The results with or without heparin are: 
     wild type antithrombin and AT-N135Q factor IIa inhibitory activity is similar to plasma antithrombin factor IIa inhibitory activity, 
     factor IIa inhibitory activity of the following mutated antithrombins: AT-R393H, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, is negligible compared with wild type antithrombin factor IIa inhibitory activity. 
     factor IIa inhibitory activity of the following mutated antithrombins: AT-S394Q, AT-S394E, AT-N135Q-S394Q and AT-N135Q-S394E, is 2 to 20 fold decreased compared with wild type antithrombin factor IIa inhibitory activity. 
     A decrease in factor IIa inhibitory activity from 2 to 20 fold compared with wild type antithrombin is reached with a composition containing one of the following mutated antithrombins: AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, or AT-N135Q-ΔS394, and AT-wt or AT-N135Q, in a varying ratio. 
     c) In vitro Evaluation of Cytoprotective Properties of the Mutated Antithrombins 
     c-1) Evaluation on Human Whole Blood 
     Cytoprotective properties of mutated antithrombins (AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393 and AT-N135Q-ΔS394) are evaluated, in vitro, on human whole blood exposed to bacterial lipopolysaccharide (LPS). 
     Venous blood was collected into tubes containing 0.11 mol/L trisodium citrate (1:10). Blood is either untreated or pre-treated with different concentration ranging from 1 to 10 IU/mL of wild type or mutated AT for 5 or 30 minutes at 37° C., and then exposed to 5 or 16 hours stimulation with 10, 50 or 100 μg/mL LPS. Blood is then centrifuged at 2300 g for 10 minutes at 12° C. and plasma supernatants stored at −80° C. until use. IL6 and TNFα protein levels from plasma supernatants are measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) (IL-6 duoset and TNFα duoset, R&amp;D System, Minneapolis, Minn., USA) 
     In the condition of the assay, addition of AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, or a composition comprising at least one of these AT variants with AT-wt or AT-N135Q, produces a significant decrease in IL6 and TNFα levels in blood samples. 
     c-2) Evaluation on Murine Mixed Cortical Cultures 
     Culturing of primary cells is performed as described (Lubetzki, C., Demerens, C., Anglade, P., Villarroya, H., Frankfurter, A., Lee, V. M. Y., Zalc, B., 1993. Proc. Natl. Acad. Sci. U.S.A. 90, 6820-6824. &lt;&lt;Even in culture, oligodendrocytes myelinate solely axons&gt;&gt;) by using brain tissue from embryos isolated from mice at 16 days post-coitum. Cerebral hemispheres are dissected from embryo brains, dissociated via trypsin digestion and the single cell suspension is seeded at 10 5  cells in 200 μl medium per well onto BioCoat® poly-L-lysine coated 96-well plates (Becton Dickinson, Bedford, Mass. 01730, USA). Cells are cultured in Bottenstein-Sato medium (GIBCO Invitrogen), supplemented with 1% FCS, 1% penicillin—streptomycin solution (Seromed) and recombinant platelet-derived growth factor AA (PDGF-AA, R&amp;D Systems) at 10 ng/mL. Cultures are grown at 37° C. and 10% CO 2  for several weeks. 
     LPS Stimulation 
     Cells are either untreated or pre-treated with various concentrations ranging from 1 to 10 IU/ml of wild type or mutated AT for 3 hours and are incubated for 48 hours with 10 ng/ml of LPS, at 37° C. and 10% CO 2 . Cell supernatants are then centrifuged at 2300 g for 10 minutes at 12° C. and stored at −80° C. until use. IL6 and TNFα protein levels from cell supernatants are measured quantitatively using a commercially available enzyme-linked immunosorbent assay (ELISA) (IL-6 duoset and TNFα duoset, R&amp;D System, Minneapolis, Minn., USA) 
     In the condition of the assay, addition of AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, or a composition comprising at least one of these AT variants with AT-wt or AT-N135Q, produces a significant decrease in IL6 and TNFα levels in cell culture supernatant. 
     Oxygen-Glucose Deprivation (OGD) 
     To induce hypoxia/reoxygenation injury, oxygen-glucose deprivation (OGD) experiments were done by treatment for 1 to 12 hours with 95% N 2 /5% CO 2  in serum-free DMEM without glucose, followed by 12 to 24 hours of exposure to normoxic conditions with 5 mmol/L glucose. Wild type or mutated AT (concentration ranging from 1 to 10 IU/mL) was added throughout the entire time of the study (13 to 36 hours). 
     Cell damage was evaluated by measuring the amount of lactate dehydrogenase (LDH) released from injured cells into the extracellular fluid 24 hours after exposure to OGD. Background LDH release was determined in control cultures not exposed to OGD and was subtracted from all experimental values 
     In the condition of the assay, addition of AT-R393H, AT-S394Q, AT-S394E, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394, or a composition comprising at least one of these AT variants with AT-wt or AT-N135Q, produces a significant decrease in LDH release from injured cells into the extracellular fluid. 
     III/ In Vivo Evaluation of Cytoprotective Properties of the Mutated Antithrombins 
     The efficiency of the mutated antithrombins AT-R393H, AT-Pro394, AT-ΔR393-S394, AT-ΔR393, AT-ΔS394, AT-N135Q-R393H, AT-N135Q-S394Q, AT-N135Q-S394E, AT-N135Q-Pro394, AT-N135Q-ΔR393-S394, AT-N135Q-ΔR393, AT-N135Q-ΔS394 as antidotes is evaluated in a murine model. 
     a) Animals 
     Wild-type C57BL/6 male mice, at least 12-week-old (JANVIER) are anesthetized using a protocol that does not modify the coagulation parameters, and in accordance with the European guidelines for animal experimentation. 
     In all experiments, antithrombin variant or placebo is administrated by intra-venous injection in the caudal vein. 
     The blood is collected by punction in cave vein into tubes containing 0.105 mol/L trisodium citrate (1:10). Platelet—poor plasma is obtained by centrifugation at 2300 g for 10 minutes at 12° C. and stored at −80° C. until use. 
     b) Experimental Protocol 
     Mouse experiments are performed to assess each antithrombin variant against placebo in two sepsis models: 1) cecum ligature and puncture (CLP), 2) lipopolysaccharide (LPS) injection. For each antithrombin variant, a first set of experiment compares inflammatory and coagulant response to sepsis with the placebo in both sepsis models. In a second set of experiment, survival after CLP and LPS injection is compared between antithrombin injected-mice and placebo-injected mice. Housing and experiments are in accordance with French regulations and European Community experimental guidelines. 
     1—Sepsis Models 
     The CLP procedure is performed as described elsewhere (Wichterman K A, Baue A E, Chaudry I H. Sepsis and septic shock—a review of laboratory models and a proposal.  J Surg Res  1980; 29: 189-201). Briefly, under isoflurane anesthesia the abdominal wall is opened through a 1-cm midline incision. The cecum is exposed and ligated about 15 mm proximal to the cecal pole with 5/0 Prolene thread (Ethicon, Somerville, N.J., USA), without stricture of the ileocecal valve. The ligated cecum is then punctured once with a 21-gauge needle. The cecum is gently pressed until a small drop of stool appeared; 1 ml of 0.9% normal saline is injected into the peritoneal cavity just before abdominal closure in sham and CLP animals. No further resuscitation is performed and no antibiotics are administered. The abdominal wall are then closed (two layers, muscle and skin; 5/0 Ethilon thread). As a control, sham surgery is performed according to the CLP procedure except that the cecum is neither ligated nor punctured. 
     In the LPS sepsis model, LPS injection (5 or 10 mg/kg) is realized intraperitoneously. Control animals will be injected with the solvent only. 
     In both models, AT is administrated by intra-venous injection in the caudal vein at a dose from about 40 to about 300 IU/kg/day. 
     2—Survival Analyses 
     For each antithrombin variant to be tested 2 groups of 15 mice each are used for CLP sepsis model:
         In the first group mice receive antithrombin variant and are subjected to CLP.   In the second group, mice receive placebo and are subjected to CLP.       

     For each antithrombin variant to be tested 2 groups of 10 mice each are used for LPS sepsis model:
         In the first group mice receive antithrombin variant and are injected with LPS.   In the second group, mice receive placebo and are injected with solvent.       

     All paired mice undergo surgery or injection on the same days. Post-operative or post-LPS injection survival is assessed every 2 hours for 48 hours and then every 8 hours until all mice have died. 
     In these experimental conditions, a longer survival in antithrombin variants-injected mice in comparison with placebo-injected mice is observed. 
     3—Evaluation of Inflammatory and Coagulant Response 
     For each antithrombin variant to be tested, 4 groups of 5 mice each are used for each sepsis model: 
     CLP model:
         In the first group, mice receive antithrombin variant and are subjected to CLP.   In the second group, mice receive placebo and are subjected to CLP.   In the third group, mice receive antithrombin variant and are sham-operated.   In the last group, mice receive placebo and are sham-operated.       

     LPS model:
         In the first group, mice receive antithrombin variant and are injected with LPS.   In the second group, mice receive placebo and are injected with LPS.   In the third group, mice receive antithrombin variant and are injected with solvent.   In the last group, mice receive placebo and are injected with solvent.       

     Blood is sampled 1 week preoperatively and at 16 hours post surgery. 
     Influence of mutated AT administration on bleeding tendancy is evaluated by examination of the abdominal cavity in Sham and CLP operated mice after sacrifice following postoperative blood sampling. 
     Antithrombin antigen levels are measured using an ELISA test (Antithrombin BioAssay™ ELISA Kit (EUROMEDEX), and antithrombin factor Xa inhibitory activity in mice&#39;s plasma is determined during the Biophen® AT kit (Hyphen BiMed, France). Inflammatory and procoagulant response to sepsis in mice injected with the antithrombin variants is evaluated by measurement of several parameters. Leukocyte, and platelet counts and hemoglobin level determinations are automated (Sci Vet ABC Animal Blood Counter, ABX Diagnostics, Montpellier, France). Plasma interleukin-6 (IL-6) and TNFα concentrations are assessed with the mouse IL-6 and TNFα Quantikine kits (R&amp;D Systems, Minneapolis, Minn., USA). Coagulation activation is evaluated by F1+2 measurement. 
     Moreover, intravascular fibrin depositions are also assessed immunohistochemically using polyclonal antibodies to fibrinogen. Fibrinogen/fibrin-bound antibodies are detected with direct immunofluorescence. Sections treated without primary antibodies serve as negative controls. 
     Using these experimental conditions, we observed a diminished inflammatory and procoagulant response to sepsis in mice injected with the antithrombin variants in comparison with placebo-injected mice. Notably, a lower IL-6 and TNFα concentrations, a reduced decline in platelet and leukocyte count, a lower thrombin generation evidenced by lower F1+2 fragments, reduced fibrin deposition in the kidneys. AT variants administration results in a 1 to 7.5 fold increase in AT circulating antigen levels.